Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153868 · ClinicalTrials.gov registry record · Phase 4
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00153868 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 43 participants.
The verdict
NCT00153868, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.
Interventions
- BIOLOGICAL darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-08-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153868
The ClinicalTrials.gov registry entry for NCT00153868 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which darbepoetin alfa is the first listed.
NCT00153868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153868 about?
NCT00153868 is a clinical study titled "A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer". This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data captu...
What is the current status of trial NCT00153868?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2003-10. Estimated completion is 2007-08-17.
What interventions are being tested in trial NCT00153868?
The interventions under investigation include: darbepoetin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00153868?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.